Tuesday, January 09, 2024 7:24:12 PM
Smitty,
Cramer won't speak with companies trading as low as NWBO, I don't think he'll speak about OTC's at all unless they're uplisting already. But I believe that if we got a major story on a national network we'd get a spike up, and yes it would fall, but not to anywhere near what we're currently trading for.
Dr. Liau now has a position with the company, so she ought to be able to openly speak for the company, not just the work being done at UCLA, but I'm not certain that she'd do it. LP is really the one who should be speaking at investors conferences, like the JP Morgan Healthcare Conference this week. In the few years that I've been an investor in NWBO, I can't think of any investors conference she's spoken at. Actually very few of them will probably invite the CEO of a penny stock, but some certainly will, and organizations like BIO routinely have conferences where participants pay to present, it may be worth their money to occasionally make such presentation to bolster the share price.
Of course all this will change with approvals and dramatically higher share prices, we just need to live through the time necessary to make that happen. Year's ago a NY Times article on Judah Folkman took a company, I think it was ENMD, from a dollar to over a hundred on curing mice, but they said if given 2 years he'd cure cancer. It fell almost as quickly as it arose, but now it's gone the other way, sometimes stocks fall on drug approvals until sufficient revenue is seen from sales for them to rise. Unless we go into approval at much, much higher share prices I don't think that will be the case with us. Shorts have cast so much doubt about approvals that I believe we'll fly when it happens, if we don't somehow fly before.
If Cramer ever mentions NWBO it will be because we're already a big success from where we are today. If he hasn't changed his rules, he won't discuss anything under $4, roughly seven times our current price. It very well may happen later this year, but when it does, we won't care that much about it. When we're $4 or more Institutional investment will increase dramatically, by $5 to $7 I wouldn't be surprised if 50% or more of our stock will be owned by Institutions. At that point the MM's won't be controlling the share price, the Institutions will have a big say.
Gary
Cramer won't speak with companies trading as low as NWBO, I don't think he'll speak about OTC's at all unless they're uplisting already. But I believe that if we got a major story on a national network we'd get a spike up, and yes it would fall, but not to anywhere near what we're currently trading for.
Dr. Liau now has a position with the company, so she ought to be able to openly speak for the company, not just the work being done at UCLA, but I'm not certain that she'd do it. LP is really the one who should be speaking at investors conferences, like the JP Morgan Healthcare Conference this week. In the few years that I've been an investor in NWBO, I can't think of any investors conference she's spoken at. Actually very few of them will probably invite the CEO of a penny stock, but some certainly will, and organizations like BIO routinely have conferences where participants pay to present, it may be worth their money to occasionally make such presentation to bolster the share price.
Of course all this will change with approvals and dramatically higher share prices, we just need to live through the time necessary to make that happen. Year's ago a NY Times article on Judah Folkman took a company, I think it was ENMD, from a dollar to over a hundred on curing mice, but they said if given 2 years he'd cure cancer. It fell almost as quickly as it arose, but now it's gone the other way, sometimes stocks fall on drug approvals until sufficient revenue is seen from sales for them to rise. Unless we go into approval at much, much higher share prices I don't think that will be the case with us. Shorts have cast so much doubt about approvals that I believe we'll fly when it happens, if we don't somehow fly before.
If Cramer ever mentions NWBO it will be because we're already a big success from where we are today. If he hasn't changed his rules, he won't discuss anything under $4, roughly seven times our current price. It very well may happen later this year, but when it does, we won't care that much about it. When we're $4 or more Institutional investment will increase dramatically, by $5 to $7 I wouldn't be surprised if 50% or more of our stock will be owned by Institutions. At that point the MM's won't be controlling the share price, the Institutions will have a big say.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
